Your session is about to expire
← Back to Search
ABM for Depression
N/A
Recruiting
Led By Bridget R. Kennedy
Research Sponsored by University of Texas at Tyler
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline rumination levels (day 1 of study) to 4-weeks post-intervention.
Awards & highlights
Study Summary
This trial looks at whether training attention away from negative info and towards positive info can reduce depression symptoms. Participants practice brief mindfulness exercises then undergo an ABM intervention with EEG equipment.
Who is the study for?
This trial is for adults over 18 who feel mildly to moderately depressed and can read and understand English. It's not suitable for those under 18, with ADHD, dyslexia, multiple sclerosis, traumatic brain injury history, current pregnancy, vision or hearing issues with computers, recent electro-shock therapy, medication changes within the last three months, substance abuse problems or epilepsy.Check my eligibility
What is being tested?
The study tests if an Attention Bias Modification (ABM) intervention after brief mindfulness training helps reduce focus on negative information in people with mild-to-moderate depression symptoms. Participants will undergo ABM sessions while wearing EEG equipment to measure brain activity.See study design
What are the potential side effects?
Since this trial involves non-invasive psychological interventions like mindfulness exercises and attention training tasks without drugs or medical procedures involved; it may have minimal side effects such as temporary discomfort from wearing EEG equipment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline rumination levels (day 1 of study) to 4-weeks post-intervention.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline rumination levels (day 1 of study) to 4-weeks post-intervention.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Amplitude changes (in microvolts) for scalp-recorded event-related potential (ERP) data.
Mood and Anxiety Symptom Questionnaire-Anhedonic Depression Subscale
Patient Health Questionnaire- 9-item
+2 moreSecondary outcome measures
Cognitive and Affective Mindfulness Scale- Revised
Five Facet Mindfulness Questionnaire
Mood and Anxiety Symptom Questionnaire-Anxious Arousal Subscale
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental GroupExperimental Treatment1 Intervention
This is group that will receive the attention bias modification intervention that is programmed to train attention to positive stimuli 100% of the time. Both groups will receive the preceding 3-day brief mindfulness training.
Group II: Placebo/Control GroupPlacebo Group1 Intervention
This is group that will receive the "sham" attention bias modification intervention that is programmed to train attention to positive stimuli 50% of the time. Both groups will receive the preceding 3-day brief mindfulness training.
Find a Location
Who is running the clinical trial?
Sarah Sass, PhDUNKNOWN
Psi ChiUNKNOWN
4 Previous Clinical Trials
215 Total Patients Enrolled
University of Texas at TylerLead Sponsor
3 Previous Clinical Trials
459 Total Patients Enrolled
1 Trials studying Depression
70 Patients Enrolled for Depression
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have trouble seeing or hearing computer instructions.You have received electro-shock therapy in the past.You have been diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).You have been diagnosed with dyslexia.You are at least 18 years old.You have been diagnosed with multiple sclerosis.You have had a serious head injury in the past.You have signs of mild to moderate depression.You possess the capacity to read and comprehend English.You currently have a problem with drug or alcohol abuse.You have been diagnosed with a seizure disorder or epilepsy.
Research Study Groups:
This trial has the following groups:- Group 1: Experimental Group
- Group 2: Placebo/Control Group
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the enrollment period still open for this research project?
"Records on clinicaltrials.gov confirm that this medical trial, which was originally listed on October 1st 2022, is actively recruiting patients. The listing has been updated as recently as April 3rd 2023."
Answered by AI
How many patients are engaged in this research endeavor?
"Affirmative. Current evidence published on clinicaltrials.gov reveals that this investigation, initially uploaded to the site on October 1st 2022, continues to recruit participants. A total of 50 patients are needed for the experiment at one research facility."
Answered by AI
What are the aims of this investigation?
"The primary metric for this study is the change in ERP amplitudes from a baseline attention task to day 3 of the trial. Secondary goals include improved Reaction Time (RT) as well as assessment of participants' anxious apprehension, mindfulness and cognitive awareness using self-report questionnaires like Penn State Worry Questionnaire, Cognitive and Affective Mindfulness Scale - Revised and Five Facet Mindfulness Questionnaire."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger